Evidence map›Paper›PMID 32103268›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2020

Inflammatory Phenotypes Predict Changes in Arterial Stiffness Following Antiretroviral Therapy Initiation.

Christine Kelly, Willard Tinago, Dagmar Alber, Patricia Hunter, Natasha Luckhurst, Jake Connolly, Francesca Arrigoni, Alejandro Garcia Abner, Ralph Kamngona, Irene Sheha and 10 more

Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01825031 (Reduction of Early mortALITY in HIV-infected African Adults and Children Starting Antiretroviral Therapy), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01825031 phase3completednot on this map

Reduction of Early mortALITY in HIV-infected African Adults and Children Starting Antiretroviral Therapy: a Randomised Controlled Trial

TypeinterventionalSponsorAnna Griffiths, MRCRan2013 to 2016Enrolled1,805ConditionsHuman Immunodeficiency VirusArmsRaltegravir, Fluconazole, Azithromycin, Albendazole, Isoniazid
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 7 institutions in 5 countries.

Christine KellyCentre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Dublin, Ireland.
Willard TinagoCentre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Dublin, Ireland.
Dagmar AlberInstitute of Child Health, University College London, London, United Kingdom.
Patricia HunterInstitute of Child Health, University College London, London, United Kingdom.
Natasha LuckhurstKingston University, London, United Kingdom.
Jake ConnollyKingston University, London, United Kingdom.
Francesca ArrigoniKingston University, London, United Kingdom.
Alejandro Garcia AbnerCentre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Dublin, Ireland.
Ralph KamngonaMalawi Liverpool Wellcome Trust Clinical Research Program, Blantyre, Malawi.
Irene ShehaMalawi Liverpool Wellcome Trust Clinical Research Program, Blantyre, Malawi.
Mishek ChammudziMalawi Liverpool Wellcome Trust Clinical Research Program, Blantyre, Malawi.
Kondwani JamboMalawi Liverpool Wellcome Trust Clinical Research Program, Blantyre, Malawi.
Jane MallewaCollege of Medicine, University of Malawi, Blantyre, Malawi.
Alicja RapalaInstitute of Cardiovascular Science, University College London, London, United Kingdom.
Robert S HeydermanInstitute of Child Health, University College London, London, United Kingdom.
Patrick W G MallonCentre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Dublin, Ireland.
Henry MwandumbaMalawi Liverpool Wellcome Trust Clinical Research Program, Blantyre, Malawi.
A Sarah Walker9MRC Clinical Trials Unit, University College London, London, United Kingdom.
Nigel KleinInstitute of Child Health, University College London, London, United Kingdom.
Saye KhooInstitute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom.
University of Liverpool · GBInstitute of Child Health · INUniversity College Dublin · IEKingston University · GBMRC Clinical Trials Unit at UCL · GBUniversity College London · GBUniversity of Malawi · MW

Funding

Department of HealthMedical Research Council MC_EX_G1100693Medical Research Council MC_EX_UU_G1100693Medical Research Council MC_UU_12023/23Medical Research Council MC_UU_12023/26Medical Research Council MR/P020526/1Wellcome Trust 099934/Z/12/A
6 · The paper itself

Abstract

backgroundInflammation drives vascular dysfunction in HIV, but in low-income settings causes of inflammation are multiple, and include infectious and environmental factors. We hypothesized that patients with advanced immunosuppression could be stratified into inflammatory phenotypes that predicted changes in vascular dysfunction on ART.

methodsWe recruited Malawian adults with CD4 <100 cells/μL 2 weeks after starting ART in the REALITY trial (NCT01825031). Carotid femoral pulse-wave velocity (cfPWV) measured arterial stiffness 2, 12, 24, and 42 weeks post-ART initiation. Plasma inflammation markers were measured by electrochemiluminescence at weeks 2 and 42. Hierarchical clustering on principal components identified inflammatory clusters.

results211 participants with HIV grouped into 3 inflammatory clusters representing 51 (24%; cluster-1), 153 (73%; cluster-2), and 7 (3%; cluster-3) individuals. Cluster-1 showed markedly higher CD4 and CD8 T-cell expression of HLADR and PD-1 versus cluster-2 and cluster-3 (all P < .0001). Although small, cluster-3 had significantly higher levels of cytokines reflecting inflammation (IL-6, IFN-γ, IP-10, IL-1RA, IL-10), chemotaxis (IL-8), systemic and vascular inflammation (CRP, ICAM-1, VCAM-1), and SAA (all P < .001). In mixed-effects models, cfPWV changes over time were similar for cluster-2 versus cluster-1 (relative fold-change, 0.99; 95% CI, .86-1.14; P = .91), but greater in cluster-3 versus cluster-1 (relative fold-change, 1.45; 95% CI, 1.01-2.09; P = .045).

conclusionsTwo inflammatory clusters were identified: one defined by high T-cell PD-1 expression and another by a hyperinflamed profile and increases in cfPWV on ART. Further clinical characterization of inflammatory phenotypes could help target vascular dysfunction interventions to those at highest risk. CLINICAL TRIALS NETWORK: NCT01825031.

Indexed as

HIV InfectionsVascular StiffnessAdultBiomarkersCD8-Positive T-LymphocytesHumansPhenotypeBiomarkersarterial stiffnessinflammatory phenotypeub-Saharan Africa

Identifiers

PMID32103268
PMCPMC7713681
OpenAlexW3008247572

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.